Quimioembolización con microesferas biocompatibles cargadas
- Ana María Cordero Cruz
- Susana Cortijo Cascajares
- María José Aguilella Vizcaíno
- M. P. Goyache-Goñi
- Alberto Herreros de Tejada López Coterilla
ISSN: 1139-7357
Año de publicación: 2011
Volumen: 13
Número: 6
Páginas: 328-337
Tipo: Artículo
Otras publicaciones en: Atención Farmacéutica
Resumen
Introduction: The purpose of this study is to compare the use frequency of DEB-TACE (Doxorubicin-eluted bead-transarterial chemoembolization) versus conventional TACE (transarterial chemoembolization) for embolizing blood vessels that feed hypervascularized malignant tumors and quantify their evolution. Method: Observational descriptive and retrospective study. The evaluation period covers January 2008 to December 2010. We studied all patients that underwent TACE chemoembolization, and from those we selected the ones treated with DEB-TACE loaded either with doxorubicin or irinotecan. Results: 38 patients were treated with DEB-TACE during 2008, 2009 and 2010: 2 patients in 2008, 11 in 2009 and 25 in 2010. 71% of patients (n = 27) were older than 60 years. 84% of patients (n = 32) had HCC (Hepatocellular Carcinoma) as the main diagnose versus the rest who had hepatic metastases (16%, n = 6). Conclusions: The DEB-TACE technique has increased throughout the period of study and, above all, its use as a first-line treatment. Its main application is for male patients (> 60 years) diagnosed with hepatic carcinomas, and treated with doxorubicin-loaded microspheres